Groll A H, Piscitelli S C, Walsh T J
Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Pharmacotherapy. 2001 Aug;21(8 Pt 2):133S-148S. doi: 10.1592/phco.21.12.133s.34507.
The pharmacodynamics of antifungal compounds involve relationships among drug concentrations, time, and antimicrobial effects in vitro and in vivo. Beyond better understanding of a drug's mode of action, characterization of these relationships has important implications for setting susceptibility breakpoints, establishing rational dosing regimens, and facilitating drug development. Important advances have been made in the experimental investigation of pharmacokinetics and pharmacodynamics of antifungal drugs; however, much remains to be learned about specific pathogens and specific sites of infection. Increased incorporation of pharmacokinetic and pharmacodynamic principles in experimental and clinical studies with antifungal agents is an important objective that will benefit the treatment and prophylaxis of life-threatening invasive fungal infections in immunocompromised patients.
抗真菌化合物的药效学涉及体外和体内药物浓度、时间与抗菌效果之间的关系。除了更好地理解药物的作用方式外,表征这些关系对于设定药敏断点、建立合理的给药方案以及促进药物开发具有重要意义。抗真菌药物的药代动力学和药效学的实验研究已取得重要进展;然而,关于特定病原体和特定感染部位仍有许多有待了解的地方。在抗真菌药物的实验和临床研究中更多地纳入药代动力学和药效学原理是一个重要目标,这将有益于免疫功能低下患者危及生命的侵袭性真菌感染的治疗和预防。